Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease

Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease.

Sponsors

Lead Sponsor: University Hospital, Ghent

Source University Hospital, Ghent
Brief Summary

Atypical hemolytic uraemic syndrome is caused by defects in the regulating factors in the alternative pathway of the complement system. Triggering can cause an uncontrolled complement activation with endothelial damage and thrombotic micro-angiopathy, especially in the kidneys. This can result in endstage renal failure. Complement activation during hemodialysis has been described as a result of contact between blood and the dialysis membrane. Our hypothesis is that patients with atypical hemolytic uraemic syndrome have a stronger complement activation during hemodialysis than patients with another underlying kidney disease. This could be a reason to treat patients with endstage renal failure due to atypical hemolytic uraemic syndrome preferentially with peritoneal dialysis instead of hemodialysis.

Overall Status Unknown status
Start Date August 2009
Completion Date July 2015
Primary Completion Date July 2015
Study Type Observational
Primary Outcome
Measure Time Frame
C3a-des-Arg measuring (as a marker of activation). at time 0, at 15 minutes, at 60 minutes and at 180 minutes
white blood cell count before and after 15 minutes of hemodialysis
Enrollment 25
Condition
Eligibility

Sampling Method: Non-Probability Sample

Criteria:

Inclusion Criteria:

- cases: endstage renal failure due to atypical hemolytic uraemic syndrome treated with hemodialysis.

- controls: endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Raymond Vanholder, MD, PhD Principal Investigator University Hospital, Ghent
Overall Contact

Last Name: Rogier Caluwé, MD

Email: [email protected]

Location
Facility: Status: Contact: Investigator: University Hospital Ghent Rogier Caluwé, MD [email protected] Raymond Vanholder, MD, PhD Principal Investigator Rogier Caluwé, MD Sub-Investigator
Location Countries

Belgium

Verification Date

December 2014

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Arm Group

Label: cases

Description: patients with endstage renal failure due to atypical uraemic syndrome treated with hemodialysis.

Label: controls

Description: patiënts with endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.

Study Design Info

Observational Model: Case Control

Time Perspective: Prospective

Source: ClinicalTrials.gov